NCT07077564View on ClinicalTrials.gov

The Efficacy of TROP2-ADC in Advanced Extrapulmonary High-Grade Neuroendocrine Neoplasms Failure of Standard Therapy

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

35

Participants

Timeline

Start Date

July 20, 2025

Primary Completion Date

July 20, 2027

Study Completion Date

July 20, 2028

Conditions

Neuroendocrine Neoplasms (Tumours)

Interventions

DRUG

Sac-TMT

Sacituzumab govitecan 5 mg/kg every 2 weeks on Day 1 of each cycle（IV）

All Listed Sponsors

lead

Second Affiliated Hospital, School of Medicine, Zhejiang University

OTHER